Diabetes and other metabolic disorders

Published on 02/03/2015 by admin

Filed under Internal Medicine

Last modified 02/03/2015

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 0 (0 votes)

This article have been viewed 1311 times

17 Diabetes and other metabolic disorders

Introduction

The study of metabolism (Box 17.1) began as long ago as the fifteenth century bc, with the first description of diabetes in the Ebers Papyrus. Metabolic diseases comprise a variety of disorders encompassing a number of medical specialties. They contribute significantly to mortality and morbidity, predominantly from cardiovascular disease. Diabetes and metabolic disorders have become more prevalent in both developed and developing countries, leading to a significant burden of chronic disease and complications related to those diseases. This increased prevalence is related to excessive calorific intake coupled with reduced physical activity. Whereas in the past metabolic diseases such as diabetes were deemed diseases of the rich, in developed countries they are now frequently diseases of lower social class, as access to healthier foods may be expensive and difficult.

The major metabolic disorders considered in this chapter are:

Diabetes mellitus and the metabolic syndrome

Diabetes is a Greek word meaning ‘a passer through; a siphon’, and mellitus derives from the Greek word for ‘sweet’. The Greeks named it thus due to the excessive amounts of urine produced by sufferers which attracted insects because of its glucose content. The ancient Chinese tested for diabetes by observing whether ants were attracted to a person’s urine.

Diabetes mellitus is the most common metabolic disorder encountered in clinical practice. It is strongly linked to obesity. Diabetes mellitus is characterized by abnormal carbohydrate and lipid homoeostasis, leading to elevation in plasma glucose, or hyperglycaemia, and abnormality of serum lipids, or dyslipidaemia. Glucose homoeostasis is modulated mainly by the release of insulin from the islet cells (β cells) of the pancreas. Diabetes develops as a result of a variable combination of absolute insulin deficiency as a result of pancreatic islet cell dysfunction and tissue insulin resistance due to reduced cellular responsiveness to insulin.

The World Health Organization (WHO) has developed a classification of diabetes mellitus based on its pathogenesis (Table 17.1). The two predominant classes of diabetes are type 1 and type 2, and clinical differences between the two are listed in Table 17.2. Type 1 is characterized by absolute insulin deficiency due to autoimmune-mediated pancreatic islet cell destruction. In contrast, type 2 diabetes is associated with a variable degree of tissue insulin resistance, leading – at least in the early stages – to high plasma insulin levels, then subsequently to relative insulin deficiency as pancreatic islet cell function fails to overcome this resistance. The diagnostic criteria for disorders of glucose metabolism based on the 75-g oral glucose tolerance test are shown in Table 17.3. Note that glycosuria itself (glucose in the urine) is not a reliable diagnostic test for diabetes mellitus.

Table 17.1 The World Health Organization classification of diabetes mellitus

Type Common subtypes/pathogenesis Treatment
Type 1 Destruction of pancreatic islet cells leading to insulin deficiency Insulin
Type 2 Ranges from predominantly insulin resistance with relative insulin deficiency (often associated with obesity) to predominantly insulin deficiency Diet/oral hypoglycaemic agents/insulin
Other types
Genetic defects of β-cell function Diabetes associated with glucokinase, hepatic nuclear factor (HNF) 1α, HNF1β, HNF4α, Neurod1 and insulin promotor factor mutations (all previously grouped under maturity-onset diabetes of the young (MODY))
Mitochondrial diabetes
Tablets or insulin depending upon genetic defect
Genetic defects of insulin action Insulin-resistance syndromes (type A insulin resistance, leprechaunism, Rabson-Mendenhall syndrome lipoatrophic diabetes) Insulin-sensitizing agents and insulin
Diseases of the exocrine pancreas Fibrocalculous pancreatic diabetes, pancreatitis, trauma/pancreatectomy, neoplasia, cystic fibrosis, haemochromatosis, others Frequently insulin required
Endocrinopathies Cushing’s syndrome, acromegaly, phaeochromocytoma, glucagonoma, hyperthyroidism, somatostatinoma, others Treatment of underlying cause
Drug or chemical induced Glucocorticoids, α-adrenergic agonists, β-adrenergic agonists, thiazides, interferon-α therapy Avoid
Uncommon forms of immune-mediated diabetes Insulin autoimmune syndrome (antibodies to insulin), anti-insulin receptor antibodies, ‘stiff man’ syndrome Variable
Other genetic syndromes associated with diabetes Down’s, Friedreich’s ataxia, Huntington’s chorea, Klinefelter’s, Lawrence-Moon-Biedl, myotonic dystrophy, porphyria, Prader-Willi, Turner’s, Wolfram’s Variable
Gestational diabetes   Diet/insulin

Table 17.2 Clinical differences between type 1 and type 2 diabetes

  Type 1 Type 2
Ketosis prone Yes Uncommon
Insulin requirement Yes (absolute insulin deficiency) Often later in disease (insulin resistance ± deficiency)
Onset of symptoms Acute Often insidious
Obese Uncommon Common
Age at onset (years) Usually <30 Usually >30
Family history of diabetes 10% 30%
Concordance in monozygotic twins 30-50% 90-100%

It has long been recognized that many people have a clustering of risk factors for cardiovascular disease. Thus, the term metabolic syndrome has been coined, with various pseudonyms of syndrome X or insulin resistance syndrome. Clinical and biochemical characteristics of the metabolic syndrome are shown in Box 17.2. People with the syndrome are at high risk of diabetes and cardiovascular disease. The condition is common among certain ethnic groups (African-Americans, Mexican-Americans, Asian Indians, Australian Aboriginals), and features can be present for up to 10 years before hyperglycaemia is detected. Vigorous treatment can reduce mortality and morbidity from cardiovascular disease.

Presenting symptoms of diabetes

Many people with type 2 diabetes may be asymptomatic at diagnosis, for example by routine screening of blood or urine, when there may be only mildly increased levels of hyperglycaemia. Once diagnosed, however, many patients do admit to some longstanding, often mild symptoms. Acute metabolic decompensation, leading to marked hyperglycaemia, occurs infrequently.

In contrast, type 1 diabetes is often abrupt in onset, and characterized by severe hyperglycaemia with acute life-threatening decompensation (diabetic ketoacidosis).

The cardinal symptoms of diabetes mellitus are weight loss, polyuria and polydipsia, and their presence should always result in an immediate test for blood glucose and urine for ketones.

Polyuria, polydipsia and nocturia

Acute hyperglycaemia causes increased urine excretion (polyuria) and, as a result, excessive thirst and water ingestion (polydipsia). These presenting symptoms of diabetes mellitus are also termed osmotic symptoms. Raised plasma glucose leads to increased renal tubular delivery of glucose, which then exceeds the resorptive capacity of the renal tubule, leading to glycosuria. Therefore, despite hyperglycaemia, people with an increased renal threshold for glucose may have no osmotic symptoms. Conversely, people with a low renal threshold for glucose may have glycosuria despite being normoglycaemic. It is for this reason that glycosuria is an unreliable feature in the diagnosis of diabetes mellitus. Nocturia is also common in patients presenting with osmotic symptoms of diabetes, and enquiry regarding the frequency of passing urine at night can be helpful in evaluating symptoms.

Other conditions can cause polyuria and polydipsia (Table 17.4). Diabetes insipidus (DI) is characterized by loss of renal concentrating capacity, owing to either loss of secretion of antidiuretic hormone (arginine vasopressin) from the posterior pituitary gland (cranial DI) or to poor renal tubular responsiveness to antidiuretic hormone (nephrogenic DI). This leads to loss of free water which, if uncorrected by increased water ingestion, can lead to severe dehydration and plasma hypertonicity. Electrolyte disturbance, such as hypercalcaemia or hypokalaemia, can impair antidiuretic hormone action and hence lead to polyuria and polydipsia. In addition, polyuria and nocturia are common symptoms of chronic renal failure.

Table 17.4 Causes of polyuria

Osmotic diuresis Diabetes mellitus, chronic renal failure, drugs
Polydipsia Psychogenic
Lack of antidiuretic hormone (ADH) Cranial diabetes insipidus due to: idiopathic, surgery, pituitary/hypothalamic tumour, familial, postpartum
Failure of response to ADH Nephrogenic diabetes insipidus due to: primary, renal tubular disorders, hypokalaemia, hypercalcaemia, drugs

Other important aspects of a diabetic history

Insulin injections

Buy Membership for Internal Medicine Category to continue reading. Learn more here